Sapra Mamta, Weiden Peter J, Schooler Nina R, Sunakawa-McMillan Ayako, Uzenoff Sarah, Burkholder Page
Department of Psychiatry, Salem VA Medical Center, 1970 Roanoke Blvd., Salem, VA 24153.
Center for Cognitive Medicine, University of Illinois, Chicago.
Clin Schizophr Relat Psychoses. 2014 Jan;7(4):199-206. doi: 10.3371/CSRP.SAWE.020813.
Most first-episode schizophrenia patients will stop their medication after their acute symptoms improve. Understanding the salient motivations and attitudes that drive adherence--as well as nonadherence--is an important part of developing strategies to prevent or delay nonadherence during the early phases of the illness.
Self-reported reasons for adherence and nonadherence among first-episode and multi-episode patients with schizophrenia were obtained from cross-sectional adherence interviews from two prospective adherence studies: one composed of a first-episode sample (n=33) and the other with recently relapsing multi-episode patients (n=16). Both groups received the Rating of Medication Influences (ROMI) Scale at approximately 16 to 20 weeks after an acute psychotic episode. The specific ROMI items were ranked in order of percentage (%) strong, and were compared both within each patient group for rank order of importance, and also compared between groups to determine the differences in specific adherence and nonadherence influences.
The doctor-patient relationship was more likely to be endorsed as a strong adherence influence in the first-episode sample (74%) than in the multi-episode sample (13%, X²=18.07, p<.01). Change in physical appearance attributed to medication was a more commonly endorsed nonadherence influence for the multi-episode sample (25%) relative to the first-episode sample (0%, X²=9.2, p<.01).
The doctor-patient relationship stands out as being the major reason for ongoing adherence for first-episode schizophrenia patients. Our post hoc interpretation is that lack of prior experience with medication and treatment elevates the importance of the relationship with the treating clinician for first-episode patients.
大多数首发精神分裂症患者在急性症状改善后会停止服药。了解促使患者坚持服药——以及不坚持服药——的显著动机和态度,是制定策略以预防或延缓疾病早期阶段不坚持服药情况的重要组成部分。
通过两项前瞻性依从性研究的横断面依从性访谈,获取首发和复发多次的精神分裂症患者自我报告的坚持服药和不坚持服药的原因:一项研究由首发样本(n = 33)组成,另一项研究有近期复发的多次发作患者(n = 16)。两组患者在急性精神病发作后约16至20周接受药物影响评定(ROMI)量表评估。将ROMI量表的具体项目按强烈程度百分比进行排序,并在每个患者组内比较重要性排序,同时在组间进行比较,以确定具体的坚持服药和不坚持服药影响因素的差异。
与多次发作样本(13%,X² = 18.07,p <.01)相比,医患关系在首发样本(74%)中更有可能被认可为强烈的坚持服药影响因素。相对于首发样本(0%,X² = 9.2,p <.01),因药物导致的外貌变化在多次发作样本(25%)中是更常见的不坚持服药影响因素。
医患关系是首发精神分裂症患者持续坚持服药的主要原因。我们事后的解释是,首发患者缺乏用药和治疗的先前经验,提高了与治疗临床医生关系的重要性。